Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
Company Details
- Employees
- 80
- Founded
- -
- Address
- 700 North Main Street, Cambridge,massachusetts 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://acrivon.com
- Keywords
- Proteomics, Drug development, Multiplex tissue imaging, Biomarker discovery, Precision Medicine, Oncology, Therapeutics.
- HQ
- Cambridge, Massachusetts
Acrivon Therapeutics, Inc. Questions
Acrivon Therapeutics, Inc.'s website is https://acrivon.com
Acrivon Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/acrivon
Acrivon Therapeutics, Inc. has
80 employees.
View email and phone details for 80
employees at Acrivon Therapeutics, Inc..
Acrivon Therapeutics, Inc.'s industry is
Biotechnology Research
Acrivon Therapeutics, Inc.'s top competitors are
Kymera Therapeutics,
Verve Therapeutics,
Voyager Therapeutics, Inc.,
Nimbus Therapeutics,
Xione Therapeutics, Inc.,
Beam Therapeutics,
Acer Therapeutics Inc.,
Mersana Therapeutics,
Tscan Therapeutics,
Kira Pharmaceuticals.
Acrivon Therapeutics, Inc.'s categories are Biotechnology Research
Acrivon Therapeutics, Inc.'s founding year is 2018
